The combined treatment with this system and cisplatin significantly delayed the growth of chemoresistant ovarian cancer, demonstrating the potential of PDK2 inhibition to redirect metabolism from glycolysis to OXPHOS, thereby suppressing tumor growth and enhancing the therapeutic efficacy of chemotherapy. Here, PDK2 is linked to ovarian carcinoma.